RANI
Rani Therapeutics Holdings, Inc. NASDAQ Listed Jul 30, 2021$0.75
-2.03%
vs $0.77
Mkt Cap $49.1M
52w Low $0.39
10.5% of range
52w High $3.87
50d MA $0.91
200d MA $1.17
P/E (TTM)
—
EV/EBITDA
—
P/B
1.2x
Debt/Equity
0.1x
ROE
-124.0%
P/FCF
-2.7x
RSI (14)
31.90
ATR (14)
$0.05
Beta
0.66
50d MA
$0.91
200d MA
$1.17
Avg Volume
1.0M
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
CIK (SEC)
Phone
408 457 3700
2051 Ringwood Avenue · San Jose, CA 95131 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.03 | -0.07 | -133.3% | 1.08 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% | — |
| Nov 6, 2025 | AMC | -0.09 | -0.12 | -33.3% | 2.27 | -14.1% | -11.0% | -7.9% | +4.3% | +9.3% | -9.0% | — |
| Aug 7, 2025 | AMC | -0.19 | -0.18 | +5.3% | 0.53 | -2.4% | -0.9% | -5.3% | +6.2% | -0.6% | +5.5% | — |
| May 13, 2025 | AMC | -0.22 | -0.22 | +0.0% | 0.48 | +16.0% | +15.6% | +2.5% | +12.2% | +9.3% | +7.0% | — |
| Mar 31, 2025 | AMC | -0.24 | -0.27 | -12.5% | 1.26 | -0.8% | -2.4% | +13.0% | -6.5% | -6.9% | -7.4% | — |
| Nov 14, 2024 | AMC | -0.22 | -0.24 | -9.1% | 2.35 | +0.9% | -3.4% | -9.7% | +0.5% | -0.5% | -0.5% | — |
| Aug 6, 2024 | AMC | -0.29 | -0.26 | +10.3% | 2.50 | +1.2% | -2.8% | -0.8% | -6.2% | +4.9% | +13.9% | — |
| May 6, 2024 | AMC | -0.23 | -0.29 | -26.1% | 7.56 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% | — |
| Mar 20, 2024 | AMC | -0.31 | -0.27 | +12.9% | 3.57 | +0.8% | +0.8% | -9.4% | -0.6% | -1.9% | -4.7% | — |
| Nov 8, 2023 | AMC | -0.47 | -0.36 | +23.4% | 1.98 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% | — |
| Aug 11, 2023 | AMC | -0.40 | -0.37 | +7.5% | 4.20 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% | — |
| May 10, 2023 | AMC | -0.47 | -0.33 | +29.8% | 4.30 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.73 | $0.74 | +0.8% | +9.6% | +4.3% | -1.2% | -1.5% | +1.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.05 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.41 | +1.4% | +0.7% | +6.4% | -4.7% | -1.4% | -0.7% |
| Oct 20 | Maxim Group | Maintains | Buy → Buy | — | $1.64 | $2.10 | +28.0% | +37.2% | +26.7% | -15.1% | -13.6% | -12.9% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.57 | $0.57 | -0.1% | +12.2% | +9.3% | +7.0% | -5.5% | -8.5% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.30 | -6.5% | -6.5% | -6.9% | -7.4% | -5.4% | +18.9% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.47 | $1.45 | -1.4% | +4.8% | -2.6% | +2.0% | -3.9% | -2.7% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.60 | -3.0% | -7.9% | -6.6% | -0.7% | +19.9% | +8.9% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.03 | -1.0% | +0.5% | -0.5% | -0.5% | +2.0% | +0.0% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +1.9% | -4.1% | -7.4% | +5.9% | -5.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.62 | -2.2% | +4.1% | +2.5% | +0.3% | +1.4% | +5.5% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.11 | +0.0% | -9.0% | +4.0% | +1.3% | -3.6% | +0.5% |
| May 9 | BTIG | Maintains | Buy → Buy | — | $7.15 | $7.23 | +1.1% | -5.2% | -6.9% | -3.2% | -5.4% | -4.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.56 | $7.55 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% |
| Mar 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.18 | $3.03 | -4.7% | -4.7% | +2.6% | +0.6% | +0.3% | +5.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.26 | $3.22 | -1.2% | -0.6% | -1.9% | -4.7% | +2.6% | +0.6% |
| Feb 6 | Wedbush | Maintains | Outperform → Outperform | — | $3.69 | $3.80 | +3.0% | +1.9% | +0.8% | +0.3% | -0.3% | -5.8% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $1.94 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.95 | +0.0% | -6.1% | +6.9% | -6.1% | -0.7% | +6.9% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | -0.8% | -7.3% | -10.7% | -1.0% | -4.3% |
| Aug 21 | BofA Securities | Maintains | Buy → Buy | — | $4.10 | $4.04 | -1.5% | -3.7% | -3.8% | +1.1% | +3.1% | -3.8% |
| Aug 17 | Wedbush | Maintains | Outperform → Outperform | — | $4.16 | $4.25 | +2.2% | -3.6% | +2.2% | -3.7% | -3.8% | +1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.30 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.64 | +0.2% | +6.5% | -3.0% | +3.6% | +1.8% | -5.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.30 | $4.31 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% |
No insider trades available.
8-K
Rani Therapeutics Holdings, Inc. -- 8-K Filing
May 29
8-K
Rani Therapeutics Holdings, Inc. -- 8-K Filing
May 27
8-K
Unknown — 8-K Filing
Rani Therapeutics secured a transformative $1.085 billion partnership with Chugai Pharmaceutical, significantly de-risking its pipeline and providing substantial funding for clinical development and commercialization efforts.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Samsara Biocapital, Llc | 8,500,000 | $11M | New | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 4,622,567 | $3M | New | Mar 2026 |
| 3 | Longaeva Partners L.p. | 2,329,459 | $2M | Added | Mar 2026 |
| 4 | Nan Fung Group Holdings Ltd | 493,584 | $363K | — | Mar 2026 |
| 5 | Millennium Management | 405,669 | $298K | Added | Mar 2026 |
| 6 | Cwa Asset Management Group, Llc | 150,000 | $202K | — | Dec 2025 |
| 7 | Kestra Private Wealth Services, Llc | 265,159 | $195K | Added | Mar 2026 |
| 8 | Ubs Group Ag | 227,223 | $167K | Added | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 188,222 | $138K | Added | Mar 2026 |
| 10 | Northern Trust Corp | 170,471 | $125K | — | Mar 2026 |
| 11 | Cygnus Capital Advisors, Llc | 115,649 | $85K | New | Mar 2026 |
| 12 | Morgan Stanley | 57,354 | $77K | Added | Dec 2025 |
| 13 | Citigroup Inc | 53,095 | $72K | New | Dec 2025 |
| 14 | Farallon Capital Management Llc | 78,000 | $57K | New | Mar 2026 |
| 15 | King Luther Capital Management Corp | 58,000 | $43K | — | Mar 2026 |
| 16 | Well Done, Llc | 52,014 | $38K | — | Mar 2026 |
| 17 | Prime Capital Investment Advisors, Llc | 27,208 | $37K | — | Dec 2025 |
| 18 | Janney Montgomery Scott Llc | 49,200 | $36K | — | Mar 2026 |
| 19 | Qube Research & Technologies Ltd | 47,508 | $35K | Reduced | Mar 2026 |
| 20 | Nine Masts Capital Ltd | 44,849 | $33K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 402,413 | $551K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 138,177 | $189K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 111,748 | $153K | Feb 2026 |
| 4 | iShares Micro-Cap ETF | 203,037 | $149K | Mar 2026 |
| 5 | Ultra-Small Company Market Fund | 114,500 | $84K | Mar 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 49,504 | $68K | Feb 2026 |
| 7 | Invesco Nasdaq Biotechnology ETF | 5,458 | $7K | Feb 2026 |
| 8 | Victory Extended Market Index Fund | 5,918 | $7K | Jan 2026 |
| 9 | ProShares Ultra Nasdaq Biotechnology | 4,504 | $6K | Feb 2026 |
Valuation
Market Cap
$49.1M
Enterprise Value
$3.8M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.05x
P/B
1.20x
P/S
15.68x
P/FCF
-2.70x
EV/EBITDA
—
Shares Out
66.1M
Financials (TTM)
Revenue
$3.2M
Net Income
-$29.4M
EBITDA
-$33.4M
Free Cash Flow
-$18.8M
Op Cash Flow
-$18.7M
EPS Basic
$-0.45
EPS Diluted
$-0.41
EPS Forward
$-0.20
Gross Margin
94.9%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$58.6M
Total Liab.
$17.1M
Total Equity
$41.5M
Cash
$49.7M
LT Debt
$2.7M
Book Value/Sh
$0.63
Debt/Equity
0.13x
Current Ratio
4.21
Quick Ratio
4.21
Returns & Growth
ROE
-124.0%
ROA
-69.9%
ROIC
-80.6%
Rev Growth YoY
+58.9%
EPS Growth YoY
+57.1%
Price Returns
2W
-14.3%
1M
+7.1%
3M
-30.6%
6M
-40.6%
12M
+70.0%
Technicals
52W High
$3.87
52W Low
$0.39
50d MA
$0.91
200d MA
$1.17
RSI (14)
31.90
ATR (14)
$0.05
Beta
0.66
Avg Volume
1.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$15.67
High
$28.00
Low
$9.00
Median
$10.00
Data updated apr 26, 2026 9:53pm
· Source: financialmodelingprep.com